Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19.
COVID-19
cluster analysis
phenotype
prognosis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
29 Oct 2020
29 Oct 2020
Historique:
received:
14
09
2020
revised:
23
10
2020
accepted:
27
10
2020
entrez:
3
11
2020
pubmed:
4
11
2020
medline:
4
11
2020
Statut:
epublish
Résumé
(1) Background: Different clinical presentations in COVID-19 are described to date, from mild to severe cases. This study aims to identify different clinical phenotypes in COVID-19 pneumonia using cluster analysis and to assess the prognostic impact among identified clusters in such patients. (2) Methods: Cluster analysis including 11 phenotypic variables was performed in a large cohort of 12,066 COVID-19 patients, collected and followed-up from 1 March to 31 July 2020, from the nationwide Spanish Society of Internal Medicine (SEMI)-COVID-19 Registry. (3) Results: Of the total of 12,066 patients included in the study, most were males (7052, 58.5%) and Caucasian (10,635, 89.5%), with a mean age at diagnosis of 67 years (standard deviation (SD) 16). The main pre-admission comorbidities were arterial hypertension (6030, 50%), hyperlipidemia (4741, 39.4%) and diabetes mellitus (2309, 19.2%). The average number of days from COVID-19 symptom onset to hospital admission was 6.7 (SD 7). The triad of fever, cough, and dyspnea was present almost uniformly in all 4 clinical phenotypes identified by clustering. Cluster C1 (8737 patients, 72.4%) was the largest, and comprised patients with the triad alone. Cluster C2 (1196 patients, 9.9%) also presented with ageusia and anosmia; cluster C3 (880 patients, 7.3%) also had arthromyalgia, headache, and sore throat; and cluster C4 (1253 patients, 10.4%) also manifested with diarrhea, vomiting, and abdominal pain. Compared to each other, cluster C1 presented the highest in-hospital mortality (24.1% vs. 4.3% vs. 14.7% vs. 18.6%;
Identifiants
pubmed: 33137919
pii: jcm9113488
doi: 10.3390/jcm9113488
pmc: PMC7693215
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Intern Med. 2020 Jun;76:36-42
pubmed: 32448770
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Front Mol Biosci. 2020 Jul 03;7:157
pubmed: 32719810
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Aging (Albany NY). 2020 Apr 8;12(7):6049-6057
pubmed: 32267833
Eur J Intern Med. 2020 Jun;76:31-35
pubmed: 32405160
Am J Epidemiol. 2013 Feb 15;177(4):292-8
pubmed: 23371353
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32675212
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Rev Clin Esp. 2020 Nov;220(8):480-494
pubmed: 32762922
Eur J Intern Med. 2020 Jun;76:43-49
pubmed: 32482597
N Engl J Med. 2020 Jul 17;:
pubmed: 32678530